Home » Topics » Disease categories and therapies » Immune

Immune
RSS

Aquila receives milestone payment from SKB under Stimulon agreement

Jan. 30, 1998

Another SMART antibody advances to clinical testing

Jan. 30, 1998

Positive U.S. phase II results for Thymoglobulin in preventing kidney transplant rejection

Jan. 28, 1998

Chesapeake Biological Laboratories and LXR to codevelop Cardiosol products

Jan. 27, 1998

Nabi's Altastaph enters phase I/II

Jan. 26, 1998

Quilimmune-P enters phase II

Jan. 23, 1998

IL-12 offers new approach to BMT in leukemia patients

Jan. 20, 1998

MedImmune and SmithKline Beecham finalize vaccine agreement

Jan. 20, 1998

Cantab and Chemo-Sero to develop chickenpox and shingles vaccines

Jan. 19, 1998

Daclizumab efficacy demonstrated in transplant recipients

Jan. 16, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...